JB Chemicals Q4 Results: Profit rises 16% YoY, margin expands; ₹7 dividend proposed

JB Chemicals and Pharmaceuticals reported a steady performance for the March quarter, closing FY25 on a strong note. Consolidated net profit rose 15.5% year-on-year to ₹145.7 crore, supported by broad-based growth across domestic formulations and contract development and manufacturing (CDMO) segments.

Revenue grew 10.2% YoY to ₹949.5 crore, while EBITDA improved 14.5% to ₹226.5 crore. Operating margin expanded to 23.9% from 23% a year ago.

The board of directors has recommended a final dividend of ₹7 per equity share (700%) for FY25, which, if approved by shareholders, will be remitted on August 13, 2025.

CEO and Wholetime Director Nikhil Chopra said, “We have closed FY25 on a strong note, in line with our strategic intent. Our domestic business continues to be one of the fastest growing in the Indian Pharma Market, with 75% of India branded formulations sales now in progressive, faster-growing segments.”

Also Read: Tata Power Q4 Results: Profit up 24% YoY, margin improves; ₹2.25 dividend proposed

Chopra added that the CDMO business bounced back in the second half, with both domestic and CDMO arms now accounting for 69% of total revenues, contributing significantly to profitability and margin strength.

Ahead of the earnings announcement, shares of JB Chemicals closed 1.94% higher at ₹1,610.50 on the BSE.